

Paras Biopharma (Biologics CDMO) Maximises Recombinant Protein Expression Facilitating Economical Scale-up of Biologics

Biopharma technology development company in the Nordics, maximises recombinant protein expression in its fully-equipped biologics production facility - Finland.


OULU, FINLAND, July 4, 2023 /EINPresswire.com/ -- The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein - fully folded / biologically active in fermentation broth in scale-up studies which can be produced to commercial scale. This advanced Biomultifold system will be in place and available for future projects to facilitate and bring down costs. Previously, Paras Biopharma achieved 5-8 g / L in expression levels of a specific therapeutic protein.

Advanced Biomultifold Technology will further facilitate higher expression & production levels for Biologics in critical care / rare disease biologics (manufacturing), thus help to bring down the scale-up biologics production costs / unit. The company is pleased to bring these developments in ongoing & upcoming projects on biologics and also to share this knowledge for client biologics CDMO work, as needed.

Full-service expertise for Scale-up Biologics Manufacturing at Paras Biopharma (Biologics CDMO) Finland, using its unique Biomultifold® Technology, can be found at <https://www.parasbiopharma.com/technology/biomultifold-technology.php>.

About Paras Biopharmaceuticals Finland Oy: Paras Biopharmaceuticals' major activities are "Biologics CDMO" Services and Biologics & Biosimilar Technology Development & Scale-up, in addition to offering co-development & licensing partnership opportunities of high-value Biologics. Paras Biopharma's unique technologies (Biomultifold®, Noblecleav® and Cytofold StructQuant®) facilitates achieving high productivity & quality of biologics.

Paras Biopharmaceuticals has established its expertise in critical areas providing biologics



Biomultifold® Microbial Expression Technologies

Focused Approach

Paras Biopharmaceuticals approach is to produce high quality Novel Biologics / Biosimilars and long therapeutic peptides in most economical manner. The company utilizes the strong scientific expertise and industrial experience of its team to achieve highest production of biologics at scale up level.

Gene Construct

One of the most advanced features of Biomultifold® E. coli based technology is achieving high biomass and production with a very economical multiple inducer. The proven Biomultifold® technology comprises of a tightly regulated expression system induced by a low cost, non toxic proprietary inducer. As the inducer is completely non-toxic, it leads to simplified post production phase of protein purification, also significantly bringing down the purification costs.

Economical Multiple Inducer

Biomultifold® Microbial High Expression Technologies

Biomultifold® provides an innovative and highly efficient process for the production of recombinant proteins using an E. coli expression system. Biomultifold® enables to achieve expression levels of milligrams of therapeutic proteins per liter of fermentation. This facilitates a very economical and cost effective system for manufacturing of recombinant proteins and their scale up production. Biomultifold® is therefore, the most suitable technology for the large scale production of Novel Biologics / Biosimilars and therapeutic products at the commercial scale.



Unique Genetic Construct

The genetic construction of proprietary plasmids of Paras Biopharmaceuticals is developed with the most optimum genetic codes selected for each amino acid of the therapeutic product. A selective combination is then developed by the most advanced optimization programs available in the industry to achieve the highest levels of protein expressions. Genes are coupled with suitable fusion partners, with a unique combination of therapeutic proteins and therapeutic peptides.

Biomultifold® -Technology Spotlight

- Achieve milligrams level of production of therapeutic proteins per liter of fermentation
- Unique Paras economical multiple inducer based high expression technology

Technology	Expression Level (g/L)
OTHER TECHNOLOGIES E. coli / Non-E. coli	~1.5
PARAS- E. coli based Biomultifold®	~12.0



CDMO, development of complex proteins from early stage to large scale, and the development of enzymes for medicinal and bioprocess purposes.

Paras Biopharmaceuticals has a fully equipped biologics production facility in Finland for the production of recombinant therapeutic products in microbial systems. The state-of-art biologics production plant includes a total floor area of 25,000 ft² and a classified cleanroom of 4,300 ft². Other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.

Paras Biopharmaceuticals has a Biologics CDMO Services pipeline <https://www.parasbiopharma.com/microbial-biologics-cdmo.php> and Biosimilars in Onco-Immunology, Urology, Osteoporosis and Rheumatoid Arthritis. For more information, please see the company pipeline: <http://www.parasbiopharma.com/biosimilars/biosimilars.php>

Mark Jackson

Paras Biopharmaceuticals Finland Oy

58442905993

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/642703884>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.